COMP <GO>
JUNS vs ABBV // GROSS PROFIT MARGIN
Jupiter Neurosciences Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: JUNS 1
— ABBV 7
▲ GROSS PROFIT MARGIN LEADER: JUNS
LAST: $2.37 (-5.20%) • MKT CAP: $3.1M
gross-margins
80.60%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
gross-margins
70.20%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (JUNS VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | JUNS | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 80.60% | 70.20% | +10.40 | JUNS | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 29.00% | -64.00 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | 3.47% | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | 24.60% | -84.60 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 6.90% | -66.90 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | — | 8.60% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 5.33 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 7/9 | -5.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 32.2 | 65.1 | -32.88 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.1M | $513.86B | -$513.86B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | JUNS REV | ABBV REV | JUNS GROSS % | ABBV GROSS % | JUNS FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $21.8K | $61.16B | 80.6% | 70.2% | -$5.4M | $17.82B |
| FY 2024 | $0 | $56.33B | — | 70.0% | -$3.9M | $17.83B |
| FY 2023 | $0 | $54.32B | — | — | -$481.0K | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
JUNS // BETA —
ABBV // BETA 1.15